Drug
Ozanimod clinical trials
Also written RPC1063, Zeposia® and BMS-986374.
- studies test it
- 37
- open now
- 4
- in phase 3
- 16
- first study started
- 2012
Keep track of what changes. Save the ozanimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 2 |
| 2018 | 7 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 7
- Phase 3
- 16
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 6
Celgene (24) · Bristol-Myers Squibb (7) · ChenXiaoChun (1) · University of Colorado, Denver (1) · I.R.C.C.S. Fondazione Santa Lucia (1) · Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (1) · Geert D'Haens (1) · The University of Texas at Dallas (1)
Often tested with
Tested in the same studies.
Phenelzine (1) · Cyclosporine (1) · Tyramine (1) · Pseudoephedrine (1)
Studies
Open first, then newest update. How each study uses ozanimod is read from its arms, and is right about nine times in ten.
Testing it · 37
- A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisRecruitingPhase 2/3Bristol-Myers SquibbNCT05076175Written as Ozanimod
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisRecruitingPhase 3Bristol-Myers SquibbNCT06408259Written as Ozanimod
- Ozanimod in Patients With Alzheimer's DiseaseRecruitingPhase 2ChenXiaoChunNCT06862960Written as Ozanimod
- Prospective Evaluation of Sequencing From antiCD-20 Therapies to OzanimodRecruitingPhase 4University of Colorado, DenverNCT06529406Written as Ozanimod
- An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical PracticeTerminatedPhase 4Bristol-Myers SquibbNCT05369832Written as Ozanimod
- An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative ColitisCompletedPhase 3CelgeneNCT02531126Written as RPC1063
- Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedPhase 3CelgeneNCT03440372Written as Ozanimod
- To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedPhase 3CelgeneNCT03915769Written as Ozanimod
- A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedPhase 3CelgeneNCT03464097Written as Ozanimod
- An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's DiseaseTerminatedPhase 3CelgeneNCT03467958Written as Ozanimod
- Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)TerminatedPhase 3CelgeneNCT04140305Written as RPC-1063
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional TherapyTerminatedPhase 2/3Bristol-Myers SquibbNCT05470985Written as Ozanimod
- A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisActive, not recruitingPhase 4Bristol-Myers SquibbNCT06396039Written as BMS-986374
- A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)TerminatedPhase 3Bristol-Myers SquibbNCT05644665Written as Ozanimod
- Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.TerminatedPhase 4I.R.C.C.S. Fondazione Santa LuciaNCT05777902Written as Ozanimod Oral Capsule
- Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseCompletedPhase 3CelgeneNCT03440385Written as Ozanimod
- Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ StudyWithdrawnPhase 4Geert D'HaensNCT06188637Written as Ozanimod Oral Capsule
- Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MSWithdrawnPhase 4The University of Texas at DallasNCT06334094Written as Ozanimod
- COVID-19 Ozanimod Intervention StudyTerminatedPhase 2Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecNCT04405102Written as Ozanimod
- A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisCompletedPhase 3CelgeneNCT02576717Written as RPC1063
Codes
What other systems call ozanimod · ClinicalTrials.gg INT000460
- MeSH (NLM) C000607776ozanimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Z80293URPVOZANIMODConfirmed FDA, NLM, Wikidata
- RxNorm 2288236Confirmed FDA, Wikidata
- Wikidata Q21098986ozanimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170279OzanimodOne source FDA
- DrugBank DB12612One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607776 | ozanimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Z80293URPV | OZANIMOD | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2288236 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21098986 | ozanimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170279 | Ozanimod | One source FDA |
| DrugBank | DB12612 | — | One source Wikidata |
Also registered as ozanimod hydrochloride (UNII 3UPR33JAAM · RxNorm 2288235).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.